



June 9, 2022

Allen K. Murray, Ph.D.
Glycan Technologies, Inc.
PO Box 17993
Irvine, CA 92623

Sent via email to: amurray1@glycantecnologies.com

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug issue, a regulation, to ban the use of glycogen assays that employ centrifugation of homogenates of patient specimens prior to the amyloglucosidase degradation of glycogen was received and processed under CFR 10.30 by this office on 06/08/2022.

It was assigned docket number FDA-2022-P-1065. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)